Why I’m Starting this Cholesterol Drug (For My Brain)
In a Nutshell
A doctor with two APOE4 genes (high Alzheimer's risk) is restarting ezetimibe—not for cholesterol/heart health, but for emerging evidence it disrupts the 14-3-3/hexokinase interaction driving protein misfolding in Alzheimer's, reducing amyloid/tau accumulation, boosting autophagy by 40%, and showing 8-fold lower dementia incidence in 4,361 patients vs. controls (per Aging Biology study with cell, worm, and retrospective human data). Despite caveats (no RCTs), its safety profile beats statins, prompting a personal low-dose trial (5 mg nightly) to test brain protection. Rapid tips: 5 mg lithium orotate, lysophosphatidylcholine DHA omega-3s (e.g., Ascentrate), and NR/NMN for NAD support, emphasizing genes aren't destiny.
These notes were generated by AI and may contain inaccuracies.
Shocking research changed my mind about this cholesterol-lowering medication, ezetimibe. It has nothing to do with cholesterol or heart health. I'm familiar with it from medical school and as a patient with one in 1 million high levels of cholesterol. Doctors have worried about my heart, but my heart is doing great and my arteries are clean. My concern is my brain. I'm at high genetic risk for Alzheimer's disease because I carry two copies of the risk gene APOE4.
Data show ezetimibe does something unexpected in the brain. It's like seeing ezetimibe as Bruce Wayne when it's also Brain Batman, fighting crime in the brain, not the heart. People die fast with dementia from infectious misfolded proteins. New study on ezetimibe and Alzheimer's—not statins, not PCSK9 inhibitors. This is not a cholesterol story. Signals like this are rare in medicine. Most interesting solutions come from looking where no one thought to look.
Road map: 1) Background on ezetimibe and Alzheimer's. 2) New study on ezetimibe and Alzheimer's with mechanistic and human data. 3) What I'm going to try next. 4) Rapid-fire tips for brain health and cognitive longevity. References in video description, newsletter, stay curious community.
Ezetimibe is a cholesterol-lowering medication that works in the gut. It selectively inhibits transporter NPC1L1 in the small intestines, responsible for absorbing dietary and biliary cholesterol. By blocking this, it reduces cholesterol delivered to the liver from intestines, prompting the liver to increase LDL receptors to pull more LDL out of circulation. Unlike statins, it doesn't inhibit cholesterol synthesis or downstream components like coenzyme Q10. It's gentler, safer, more benign.
Sign in to read the full notes
Get access to AI-generated notes, topic timestamps, and more.